Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.146 EUR | -0.35% | -1.72% | -36.40% |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
06-13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
Business Summary
At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Number of employees: 61
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Chief Operating Officer | - | - | |
Laurent Guerci
PRN | Corporate Officer/Principal | - | 23-07-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Laura Coruzzi
BRD | Director/Board Member | 71 | 15-05-26 |
Karen Noël
BRD | Director/Board Member | 51 | 17-06-08 |
Emmanuel Huynh
CHM | Chairman | 54 | 19-08-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 32,459,012 | 22,076,290 ( 68.01 %) | 253,928 ( 0.7823 %) | 68.01 % |
Company contact information
ABIONYX Pharma SA
33-43, avenue Georges Pompidou Bâtiment D2
31130, Balma
+33 5 62 24 97 06
http://www.abionyx.comSector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+25.50% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.87% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- ABNX Stock
- 609 Stock
- Company ABIONYX Pharma